Sign In
Buy DXCM
$82.66
-4.28 (-4.92%)
At Close: Aug 05, 2026
S&P 500 Medtech Play DexCom Leads Five Stocks Near Buy Points
08:00am, Saturday, 13'th May 2023
These five stocks offer investors a variety of options across multiple sectors. The post S&P 500 Medtech Play DexCom Leads Five Stocks Near Buy Points appeared first on Investor's Business Daily.
Dexcom Shows Strength As Glucose Monitor Attracts Buyers
01:25pm, Thursday, 11'th May 2023
Dexcom stock rebounds as glucose monitor maker sees expanding market. The med tech raised revenue guidance in its Q1 earnings report.
3 HealthTech Stocks to Watch as Digital Health Transforms the Industry
12:40pm, Thursday, 04'th May 2023
Increasingly, technologies other than drugs are working to improve patient health. From diagnostic systems like MRIs and CAT scans to high-tech glucose monitoring systems to devices that destroy tumor
Is Dexcom a Good Stock to Buy Now?
05:14am, Tuesday, 02'nd May 2023
Dexcom recently reported results from the first quarter of 2023 and reactions were mixed. Wall Street analysts cheered but shares of Dexcom fell a couple of percentage points.
DexCom (DXCM) Q1 Earnings Beat Estimates, Volumes Remain Strong
12:56pm, Friday, 28'th Apr 2023
DexCom's (DXCM) first-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
DexCom (DXCM) Q1 Earnings and Revenues Beat Estimates
07:01pm, Thursday, 27'th Apr 2023
DexCom (DXCM) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.08 per share a year ago.
2 Growth Stocks That Could Double in 5 Years
10:23am, Thursday, 27'th Apr 2023
Vertex Pharmaceuticals will significantly expand its lineup over the next five years. DexCom's continuous glucose monitoring system should have a long growth runway.
2 Monster Stocks to Buy Without Any Hesitation
10:20am, Tuesday, 25'th Apr 2023
Eli Lilly's shares are up more than 235% over the past five years. Mounjaro is expected to be a blockbuster drug for Lilly.
Sell the News? 5 Reasons Tech May Pullback
02:28pm, Monday, 24'th Apr 2023
Though the medium-term trend remains intact for tech, some subtle signs of weakness are appearing beneath the surface. Andrew Rocco breaks it down.
Big Tech Earnings & Economic Numbers: 3 Ways to Survive the Week Ahead
09:10am, Monday, 24'th Apr 2023
Many of the FANG stocks are slated to report earnings this week. Today, we will lay out how investors can best navigate the action packed week ahead.
Riding the Wave: These 3 Industry Groups are Making a Splash with Expected Money Inflows
10:39am, Thursday, 20'th Apr 2023
Markets have been known to have periods of "nasty" industry group rotation. Get ahead of the curve with these 3 under-the-radar groups.
Are Medical Stocks Lagging DexCom (DXCM) This Year?
11:29am, Wednesday, 19'th Apr 2023
Here is how DexCom (DXCM) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
The Medicare Decision That Propelled Dexcom Stock Closer To A Breakout
12:23pm, Monday, 17'th Apr 2023
Dexcom stock closed in on a breakout Monday after Medicare officials announced the biggest-ever expansion for coverage of CGMs in the U.S. The post The Medicare Decision That Propelled Dexcom Stock Cl
Healthcare Innovation Drives Medical Device Makers To New Highs
08:16am, Monday, 17'th Apr 2023
The healthcare sector has been looking fit in the past month, with medical products makers Stryker Corp. (NYSE: SYK) and Boston Scientific Corp. (NYSE: BSX) rallying to all-time highs, while sector pe
DexCom Stock Sets Up; Can It Catch Up To Company's Torrid Growth?
04:28pm, Thursday, 13'th Apr 2023
Analysts expect earnings to increase 22% this year and 38% in 2024. The post DexCom Stock Sets Up; Can It Catch Up To Company's Torrid Growth?
